RedHill Biopharma hosting R&D day on acute gastroenteritis, IBS-D treatment: 3 notes

RedHill Biopharma is hosting an analysts and investors R&D Day to discuss it drug Bekinda, a treatment for acute gastroenteritis and irritable bowel syndrome with diarrhea.

Advertisement

Here’s what you should know:

1. The event will be in New York City on April 27, from 8 a.m. to 10 a.m. EST, with a live stream available online under the investors section.

2. RedHill’s executive team and key opinion leaders will discuss Bekinda and applicable market aspects.

3. RedHill expects results from its phase III study on Bekinda in the second quarter of fiscal year 2017.

More articles on gastroenterology:
Bowel cancer mortality rates drop 30% — 4 study insights
GI leader to know: Dr. Louis Leite of Pennsylvania Gastroenterology
2 new GI-driven ASCs & facilities — March 2017

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • Birmingham (Ala.) Gastroenterology has opened a clinic in Jasper, Ala., expanding access to digestive health services in the region, the…

  • Premier Health Partners has acquired Dayton, Ohio-based Digestive Specialists, according to a notice posted on the website of law firm…

Advertisement

Comments are closed.